Quarterly report [Sections 13 or 15(d)]

Fair Value Measurements (Tables)

Fair Value Measurements (Tables)

6 Months Ended

Dec. 31, 2025

Schedule of information by level for financial assets and liabilities that are measured at fair value on a recurring basis

The following tables provide information by level for financial assets and liabilities that are measured at fair value on a recurring basis (in thousands).


		* *	Total
			carrying
			value as of			Fair Value Measurements Using
	Balance Sheet Location		December 31,			Inputs Considered as
			2025			Level 1		Level 2		Level 3
Assets
Exchange traded securities⁽¹⁾	Other current assets		$	6,666		$	6,666	$	—	$	—
Notes receivable⁽²⁾	Other current assets			4,873			—		—		4,873
Notes receivable⁽²⁾	Other assets			7,179			—		—		7,179
Total assets			$	18,718		$	6,666	$	—	$	12,052

Liabilities
Derivatives designated as hedging instruments - net investment hedge	Other long-term liabilities		$	16,317		$	—	$	16,317	$	—
Total liabilities			$	16,317		$	—	$	16,317	$	—

⁽¹⁾Exchange traded securities received from the buyer in the sale of Exosome Diagnostics.

⁽²⁾Notes receivable relate to the divestiture of our businesses held-for-sale.


		* *	Total
			carrying
			value as of			Fair Value Measurements Using
	Balance Sheet Location		June 30,			Inputs Considered as
		* *	2025			Level 1		* *	Level 2		* *	Level 3
Assets
Derivatives designated as hedging instruments - cash flow hedges	Other current assets		$	2,843		$	—		$	2,843		$	—
Note receivable⁽¹⁾	Other current assets			3,078			—			—			3,078
Note receivable⁽¹⁾	Other assets			2,184			—			—			2,184
Total assets			$	8,105		$	—		$	2,843		$	5,262

Liabilities
Derivatives designated as hedging instruments - net investment hedge	Other long-term liabilities		$	18,034		$	—		$	18,034		$	—
Total liabilities			$	18,034		$	—		$	18,034		$	—

(1)Notes receivable relates to the divestiture of our business held-for-sale.

Schedule of contractual amounts of the outstanding instruments

The following table presents the contractual amounts of the Company's outstanding instruments (in millions):


		* *	December 31,		June 30,
Instruments	Designation	* *	2025		2025
Forward starting swaps⁽¹⁾	Cash flow hedge		$	—	$	200
Cross-currency swap⁽²⁾	Net investment hedge			130		140

⁽¹⁾ In May 2021, the Company entered into a forward starting swap designated as a cash flow hedge on forecasted debt based on $200 million of notional principal. The effective date of the swap was November 2022 and matured in November 2025.

⁽²⁾ In July 2023, the Company entered into a pay-fixed rate, receive-fixed rate cross-currency swap contract with a total notional amount of $150 million that was designated as a hedge to lock in the Swiss franc (CHF) rate for a portion of the Company's CHF net investment in its Lunaphore subsidiary in Switzerland. The objective of the hedge is to protect the net investment in the Company's CHF-denominated operations against changes in the spot exchange rates, on a pre-tax basis. The hedging instrument has three interim settlement dates, which will reduce the notional on the hedging instrument by $10 million at each interim date, and will reduce the notional to $110 million at maturity.

Schedule of pretax amount of the gains and losses on our hedging instruments and the classification of those gains and losses

The pretax amount of the gains and losses on our hedging instruments and the classification of those gains and losses within our Condensed Consolidated Financial Statements for the quarter and six months ended December 31, 2025 and 2024 were as follows (in thousands):


		(Gain) Loss Recognized in Accumulated Other Comprehensive Loss
	* *	Quarter Ended					Six Months Ended
		December 31,					December 31,
	* *	2025		* *	2024		2025		2024
Cash flow hedges
Forward starting swaps		$	1,410		$	1,689	$	4,419	$	6,699
Net investment hedges
Cross-currency swap			336			(7,690)		(381)		(2,525)
Total		$	1,746		$	(6,001)	$	4,038	$	4,174


		(Gain) Loss Reclassified into Income
	* *	Quarter Ended					Six Months Ended
		December 31,					December 31,				Income Statement
	* *	2025		* *	2024		2025		2024		Classification
Cash flow hedges
Forward starting swaps		$	(757)		$	(2,155)	$	(2,678)	$	(4,754)	Interest expense
Net investment hedges
Cross-currency swap			(660)			(660)		(1,273)		(1,442)	Interest expense
Total		$	(1,417)		$	(2,815)	$	(3,951)	$	(6,196)